01465nas a2200277   4500000000100000008004100001260001300042653001200055653001100067653002100078653001200099653000900111653002400120653002500144653001400169653001500183100001800198700001700216700001300233245009100246856004100337300000900378490000700387520077900394022001401173       1993                            d  c1993 Mar10aAnimals10aFemale10aFluoroquinolones10aleprosy10aMice10aMice, Inbred BALB C10aMycobacterium leprae10aOfloxacin10aQuinolones1 aFranzblau S G1 aParrilla M L1 aChan G P00aSparfloxacin is more bactericidal than ofloxacin against Mycobacterium leprae in mice.  uhttp://ila.ilsl.br/pdfs/v61n1a11.pdf  a66-90 v613 a<p>The comparative bactericidal activities of sparfloxacin and ofloxacin against Mycobacterium leprae in mice were determined using the proportional bactericidal test at doses of 12.5 mg/kg-100 mg/kg. Significant bactericidal activity was found at 12.5 mg/kg sparfloxacin and 25 mg/kg ofloxacin. Sparfloxacin was significantly more bactericidal than ofloxacin at all doses, and the results with 25 mg/kg sparfloxacin were nearly identical to those obtained with 100 mg/kg ofloxacin. These results, together with pharmacokinetic and toxicological data in mice and man, suggest that sparfloxacin may have a higher therapeutic index than ofloxacin in leprosy, and that the tentative standard dosage of 200 mg sparfloxacin daily should be appropriate for a clinical trial.</p>
  a0148-916X